Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequencing Topoisomerase Inhibitors in Extensive Stage SCLC
NCT00057837Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Jul 2004
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of topotecan liposome and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in small cell lung cancer (SCLC) (2 arms), sponsored by Eastern Cooperative Oncology Group. Primary endpoint: Proportion of Patients With Objective Response by Solid Tumor Response Criteria (RECIST). Started Jul 2004; status: completed.
02
Drugs
topotecan liposomeirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00057837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00057837.